- Home
- ZTEK vs PRQR Comparison
ZTEK vs PRQR Comparison
Compare ZTEK & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- PRQR
- Stock Information
- Founded
- ZTEK 2008
- PRQR 2012
- Country
- ZTEK Canada
- PRQR Netherlands
- Employees
- ZTEK N/A
- PRQR N/A
- Industry
- ZTEK Major Chemicals
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- ZTEK Industrials
- PRQR Health Care
- Exchange
- ZTEK Nasdaq
- PRQR Nasdaq
- Market Cap
- ZTEK 165.9M
- PRQR 163.3M
- IPO Year
- ZTEK N/A
- PRQR 2014
- Fundamental
- Price
- ZTEK $1.52
- PRQR $1.66
- Analyst Decision
- ZTEK
- PRQR Strong Buy
- Analyst Count
- ZTEK 0
- PRQR 7
- Target Price
- ZTEK N/A
- PRQR $9.00
- AVG Volume (30 Days)
- ZTEK 51.2K
- PRQR 470.6K
- Earning Date
- ZTEK 06-26-2025
- PRQR 05-08-2025
- Dividend Yield
- ZTEK N/A
- PRQR N/A
- EPS Growth
- ZTEK N/A
- PRQR N/A
- EPS
- ZTEK N/A
- PRQR N/A
- Revenue
- ZTEK $44,936.00
- PRQR $21,212,711.00
- Revenue This Year
- ZTEK N/A
- PRQR $2.87
- Revenue Next Year
- ZTEK N/A
- PRQR N/A
- P/E Ratio
- ZTEK N/A
- PRQR N/A
- Revenue Growth
- ZTEK 92.38
- PRQR 85.91
- 52 Week Low
- ZTEK $0.50
- PRQR $1.07
- 52 Week High
- ZTEK $1.84
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- ZTEK 51.88
- PRQR 52.16
- Support Level
- ZTEK $1.52
- PRQR $1.66
- Resistance Level
- ZTEK $1.62
- PRQR $1.83
- Average True Range (ATR)
- ZTEK 0.11
- PRQR 0.10
- MACD
- ZTEK -0.03
- PRQR -0.00
- Stochastic Oscillator
- ZTEK 34.98
- PRQR 48.48
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.